Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSI-SAVE: Increasing the dosing interval of osimertinib in EGFR-mutated NSCLC
2024-514693-47-01Phase 4Authorised
- Sponsor
- Erasmus MC
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of osimertinib in EGFR-mutated non-small cell lung cancer, sponsored by Erasmus MC. Primary endpoint: Progression-free survival. Planned start Oct 2025; status: authorised.
02
Drugs
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on 2024-514693-47-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514693-47-01.